NCT06151509View on ClinicalTrials.gov

90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment

NANot yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Adverse Effect
Interventions
DRUG

Alpha-Agonist

An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

DRUG

α-adrenergic receptor agonist

An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

All Listed Sponsors
lead

General Hospital of Ningxia Medical University

OTHER

NCT06151509 - 90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment | Biotech Hunter | Biotech Hunter